

CLAIMS

1. A monoclonal antibody for use in therapy, wherein the therapy comprises a method of administering the monoclonal antibody to a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising the monoclonal antibody and a pharmaceutically acceptable carrier,
wherein the monoclonal antibody is administered in an amount of about 500 mg to 5000 mg per dose, and

wherein the monoclonal antibody comprises a heavy chain variable complementarity-determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain variable CDR2 comprising the amino acid sequence of SEQ ID NO: 2, a heavy chain variable CDR3 comprising the amino acid sequence of SEQ ID NO: 3, a light chain variable CDR1 comprising the amino acid sequence of SEQ ID NO: 13, a light chain variable CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a light chain variable CDR3 comprising the amino acid sequence of SEQ ID NO: 15.

2. A pharmaceutical composition comprising a monoclonal antibody and a pharmaceutically acceptable carrier for use in therapy, the therapy comprising administering the monoclonal antibody to a subject in need thereof,
wherein the monoclonal antibody is administered in an amount of about 500 mg to 5000 mg per dose, and

wherein the monoclonal antibody comprises a heavy chain variable complementarity-determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain variable CDR2 comprising the amino acid sequence of SEQ ID NO: 2, a heavy chain variable CDR3 comprising the amino acid sequence of SEQ ID NO: 3, a light chain variable CDR1 comprising the amino acid sequence of SEQ

ID NO: 13, a light chain variable CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a light chain variable CDR3 comprising the amino acid sequence of SEQ ID NO: 15.

3. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any preceding claim, wherein the monoclonal antibody comprises a heavy chain variable CDR1 having the amino acid sequence of SEQ ID NO: 1, a heavy chain variable CDR2 having the amino acid sequence of SEQ ID NO: 2, a heavy chain variable CDR3 having the amino acid sequence of SEQ ID NO: 3, a light chain variable CDR1 having the amino acid sequence of SEQ ID NO: 13, a light chain variable CDR2 having the amino acid sequence of SEQ ID NO: 14, and a light chain variable CDR3 having the amino acid sequence of SEQ ID NO: 15.

4. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any preceding claim, wherein the monoclonal antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 25, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 26.

5. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any preceding claim, wherein the monoclonal antibody comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO: 25, and a light chain variable region having the amino acid sequence of SEQ ID NO: 26.

6. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any preceding claim, wherein the monoclonal antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 27, and a light chain comprising the amino acid sequence of SEQ ID NO: 28.

7. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any preceding claim, wherein the monoclonal antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO: 27, and a light chain having the amino acid sequence of SEQ ID NO: 28.

8. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any preceding claim, wherein the pharmaceutical composition further comprises histidine, sucrose, polysorbate 20, and ethylenediamine tetra-acetic acid.

9. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any preceding claim, wherein the pharmaceutical composition has a pH of about 5-6.

10. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any preceding claim, wherein the monoclonal antibody is administered in an amount of about 1000 mg to about 3000 mg per dose.

11. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any one of claims 1-9, wherein the monoclonal antibody is administered in an amount of about 2000 mg to about 5000 mg per dose.

12. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any one of claims 1-9 and 11, wherein the monoclonal antibody is administered in an amount of about 3000 mg to about 5000 mg per dose.

13. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any preceding claim, wherein the monoclonal antibody is administered in an amount of about 500 mg, 750 mg, 1000 mg, 1200 mg, 1250 mg, 1400 mg, 1500 mg, 1600 mg, 1750 mg, 1800 mg, 2000 mg, 2200 mg, 2250 mg, 2400 mg, 2500 mg, 2600 mg, 2750 mg, 2800 mg, 3000 mg, 3200 mg, 3250 mg, 3400 mg, 3500 mg, 3600 mg, 3750 mg, 3800 mg, 4000 mg, 4200 mg, 4250 mg, 4400 mg, 4500 mg, 4600 mg, 4750 mg, 4800 mg, or 5000 mg, or any value in between, per dose.

14. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any one of claims 1-10 and 13, wherein the monoclonal antibody is administered in an amount of about 1000 mg per dose.

15. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any preceding claim, wherein the monoclonal antibody is administered in an amount of about 3000 mg per dose.

16. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any one of claims 1-10 and 11-13, wherein the monoclonal antibody is administered in an amount of about 4000 mg per dose.

17. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any one of claims 1-10 and 11-13, wherein the monoclonal antibody is administered in an amount of about 5000 mg per dose.

18. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any preceding claim, wherein the pharmaceutical composition is administered by intravenous infusion.

19. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any preceding claim, wherein the pharmaceutical composition is administered as more than one dose.

20. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of claim 19, wherein the administration of each dose is separated by a period of about 4 weeks.

21. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any preceding claim, wherein the subject in need of a treatment of Alzheimer's Disease.

22. The ~~method~~monoclonal antibody for use or pharmaceutical composition for use of any preceding claim, wherein the subject is in need of a treatment of early Alzheimer's Disease, prodromal Alzheimer's Disease, or mild Alzheimer's Disease.